Acrivon Other Assets from 2010 to 2025

ACRV Stock   5.36  0.22  4.28%   
Acrivon Therapeutics, Other Assets yearly trend continues to be fairly stable with very little volatility. Other Assets will likely drop to 0.86 in 2025. During the period from 2010 to 2025, Acrivon Therapeutics, Other Assets regression line of quarterly data had mean square error of 14.7 B and geometric mean of  35,338. View All Fundamentals
 
Other Assets  
First Reported
2010-12-31
Previous Quarter
0.9
Current Value
0.86
Quarterly Volatility
163 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Acrivon Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acrivon Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 479.9 K, Selling General Administrative of 25.5 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.85. Acrivon financial statements analysis is a perfect complement when working with Acrivon Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Acrivon Therapeutics, Correlation against competitors.

Latest Acrivon Therapeutics,'s Other Assets Growth Pattern

Below is the plot of the Other Assets of Acrivon Therapeutics, Common over the last few years. It is Acrivon Therapeutics,'s Other Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acrivon Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Other Assets10 Years Trend
Slightly volatile
   Other Assets   
       Timeline  

Acrivon Other Assets Regression Statistics

Arithmetic Mean328,313
Geometric Mean35,338
Coefficient Of Variation49.65
Mean Deviation123,117
Median407,000
Standard Deviation163,013
Sample Variance26.6B
Range407K
R-Value(0.69)
Mean Square Error14.7B
R-Squared0.48
Significance0
Slope(23,790)
Total Sum of Squares398.6B

Acrivon Other Assets History

2025 0.86
2024 0.9
2023 1.0
2021388 K

About Acrivon Therapeutics, Financial Statements

Acrivon Therapeutics, investors use historical fundamental indicators, such as Acrivon Therapeutics,'s Other Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Acrivon Therapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Assets 0.90  0.86 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.